Sofosbuvir / Velpatasvir: 9 agencies, 2016–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused sofosbuvir / velpatasvir: all 14 decisive outcomes across 8 agencies were positive or positive with restrictions.
Assessment has run over 9.2 years, from 27 Sep 2016 at TLV (Sweden) to 29 Dec 2025 at CONITEC (Brazil).
No assessment is on file from PBAC (Australia) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 3 of 18 records date from 2023 or later.
3 distinct indication wordings are recorded for sofosbuvir / velpatasvir by the agencies that label one in English (AWMSG and SMC).
TLV (Sweden) was first to assess sofosbuvir / velpatasvir, on 27 Sep 2016; CONITEC (Brazil) did not open a file until 29 Dec 2025 — an unusually long tail of 9.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 5 of 14 decisive outcomes narrowed sofosbuvir / velpatasvir to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
5 of the 9 agencies here assessed sofosbuvir / velpatasvir more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for sofosbuvir / velpatasvir.
The full ledger for sofosbuvir / velpatasvir reads 9 recommended, 5 restricted, 2 no benefit and 1 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 12 Jul 2024 | Ny beredningsform av Epclusa ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 15 Feb 2023 | Treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to less than 18 years of age | recommended (licence extension for paediatric use) | source |
| G-BA (Germany) | 4 Aug 2022 | Epclusa — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 20 Apr 2022 | Indication extension | SMR substantial · ASMR IV | source |
| NYE METODER (Norway) | 22 Nov 2020 | Behandling av kronisk hepatitt C hos pasienter i alderen 6 år og eldre og som veier minst 17 kg. | introduced | source |
13 further decisions for sofosbuvir / velpatasvir, across 8 agencies, are not shown here. They include the most recent record on file, 29 Dec 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- sofosbuvir / velpatasvir / voxilaprevir — divergent outcome (recommended vs no benefit) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 18 decisions for sofosbuvir / velpatasvir from 9 agencies, 2016 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.